Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birabresib - OncoEthix

Next Previous
X
Search
Drug Profile

Birabresib - OncoEthix

Alternative Names: MK 8628; OTX 015; Y-803

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Merck & Co; Mitsubishi Tanabe Pharma Corporation; OncoEthix
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Small molecules; Triazoles
  • Mechanism of Action BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Preclinical Urogenital cancer
  • No development reported Haematological malignancies
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from preclinical studies in Glioblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 14 May 2023 Pharmacodynamics data from a preclinical study in Bladder cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 27 Dec 2022 Preclinical development is ongoing in Urogenital cancer in Switzerland (Unspecified)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top